PRAS40 is an mTOR binding protein which has complex effects on cell metabolism. Our study tests the hypothesis that PRAS40 knockdown (KD) in C2C12 myocytes will increase protein synthesis via up-regulation of mTOR-S6K1 pathway. PRAS40 KD was achieved using lentiviruses to deliver shRNA targeting PRAS40 or a scrambled control. C2C12 cells were used as either myoblasts or differentiated to myotubes. Knockdown reduced PRAS40 mRNA and protein content by greater than 80% of time-matched control values but did not alter the phosphorylation of mTOR substrates, 4E-BP1 or S6K1, in either myoblasts or myotubes. No change in protein synthesis in myotubes was detected as measured by the incorporation of 35 Smethionine. In contrast, protein synthesis was reduced 25% in myoblasts. PRAS40 KD in myoblasts also decreased proliferation rate with an increased percent of cells retained in G1
Introduction
Skeletal muscle is a dynamic and plastic tissue that undergoes both acute and chronic changes in response to various external stimuli. Muscle serves as the largest protein reservoir in the body and can be used as an energy source when the physiological need arises. Protein stores in muscle are maintained by the ingestion of protein/amino acid -containing meals which stimulate protein synthesis and suppress protein breakdown [1, 2] . Conversely, during periods of starvation or disuse, muscle protein breakdown exceeds protein synthesis [3] , providing amino acids to support hepatic gluconeogenesis and acute phase protein synthesis. Protein synthesis in general is largely regulated at the level of translation initiation which in turn is regulated by mTOR (mammalian target of rapamycin) [4, 5] .
Normal cellular function is dependent on the integration and regulation of cell signaling pathways governing cell cycle, protein synthesis and degradation, cell proliferation, and apoptosis. The Serine (S)/Threonine (T) protein kinase mTOR plays an important role in these pathways [6] [7] [8] , and disregulation of mTOR signaling networks leads to numerous diseases [9] . mTOR is contained within two distinct complexes, mTORC1 and mTORC2 [5, 10, 11] . The former complex is composed of mTOR, raptor, LST8/G-protein β-subunit like protein (GβL), Proline Rich Akt Substrate 40kD (PRAS40), and DEPTOR [12] .
Exposure of muscle to growth factors and nutrients increases protein translation initiation via the mTOR pathway thereby stimulating protein synthesis [13] . In response to growth factor signaling, the Phosphoinositide 3-kinases (PI3K) pathway enhances Akt via Phosphoinositide Dependent Kinase (PDK). Activated Akt then phosphorylates PRAS40 on T246 releasing PRAS40 from the mTOR/raptor complex and enhances its binding to the cellular anchor protein 14-3-3 [14, 15] . Conversely, in the absence of growth factors, PRAS40 is hypophosphorylated and remains bound to mTOR-raptor and thereby inhibits binding of other mTOR substrates, such as the ribosomal protein S6 kinase (S6K1) and the translational repressor Molecular Medicine www.molmed.org UNCORRECTED PROOF eukaryotic initiation factor 4E binding protein (4E-BP1), thereby suppressing cap-dependent protein translation initiation [15] .
The necessity of mTOR activation and subsequent phosphorylation of S6K1 and 4E-BP1 has been demonstrated previously, however, the role of PRAS40 in mTORC1 is poorly defined.
Present data place PRAS40 either at the level of mTOR (as an Akt substrate) or as a direct downstream substrate of mTOR where it is phosphorylated on S183 [16, 17] . Several reports have implicated PRAS40 as a negative regulator of mTOR via its inhibition of mTOR substrates, while in contrast others have shown PRAS40 is required for mTOR signaling [18] . These opposing data have given rise to controversies regarding the role of PRAS40 in regulating protein translation initiation via mTORC1. Despite several reports implicating PRAS40 as a regulator of protein translation initiation in a variety of cells, there is a paucity of information related to its role in skeletal muscle. Given the pivotal role mTOR plays in response to environmental cues in regulating protein translation initiation, cell cycle and proliferation, it is reasonable to suspect that one or more of these mTOR functions are altered by PRAS40 in myocytes. Therefore, the purpose of our current investigation was to examine changes in C2C12 myocyte protein synthesis, cell proliferation and cell cycle in response to PRAS40 knockdown using shRNA based in vitro experimental approaches.
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Materials and Methods
Cell culture. C2C12 myoblasts (American Type Culture Collection, Manassas, VA)
were maintained in Dulbecco's minimum essential medium (DMEM; Invitrogen; Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/ml), streptomycin (100 µg/ml) (all from Mediatech, Herndon, VA) under 5% CO 2 at 37°C. Myoblasts were subcultured and when 100% confluent, the cells were switched to differentiation medium (DM) consisting of DMEM with the above antibiotics-antimycotics and 2% horse serum (Hyclone, Logan, UT) to promote myoblast fusion and differentiation to myotubes. Cells were differentiated for 6 days before experimental manipulation. Myotubes were provided with fresh differentiation medium on day 6 and experiments were performed on day seven. To simulate basal mTOR activity, experiments measuring protein synthesis and the phosphorylation of mTOR substrates were performed with serum-free DMEM without antibiotics-antimycotics. 5-Aminoimidazol-4-carboximide ribonucleoside (AICAR; Toronto Research Chemicals, Ontario, Canada) when present was added at a final concentration of 2 mM for 8 h. Insulin-like growth factor (IGF) -I when present was used at final concentration of 100 ng/ml for the last 20 min of the experiment.
These doses maximally suppress and activate protein synthesis in C2C12 cells, respectively [19, 20] .
shRNA interference. The lentiviral plasmid pLKO.1-mPRAS40 used was that described by Vander Haar et al [21] and targeted the mouse sequence 5'-GAG CCC ACT GAA ACA GAG ACA-3'; the scramble shRNA was used as a negative control as previously reported [15] 
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grown in DMEM media; 80-85% confluent plates were rinsed once with Opti-MEM media (Invitrogen) and then incubated with Opti-MEM media for 4 h before transfections. psPAX2 and pMD2.G along with either scramble or pLKO.1-mPRAS40 were added after mixing with Lipofectamine 2000 as per manufacturer's instructions (Invitrogen). Opti-MEM media was changed after overnight incubation with DMEM containing 10% FBS without antibiotics to allow cells to take up the plasmids and recover. Culture media was collected at 36 h and 72 h posttransfection for viral particles. Viral particles present in the supernatant were harvested after a 15 min spin at 1500 x g to remove cellular debris. The supernatant was further filtered using a 0.45 μm syringe filter. Supernatant containing virus was either stored at -80 ºC for long-term storage or at 4 ºC for immediate use. C2C12 cells at 60% confluence were infected twice overnight with 3 ml of viral supernatant containing 8 µg/ml polybrene in serum free -antibiotic free DMEM. Fresh DMEM media containing 10% FBS, antibiotics, and 2 μg/ml puromycin (Sigma, St. Louis, MO) was added the next day. Cells that survived under puromycin selection were either harvested (as stable cells) and stored or used immediately.
35
S-methionine labeling. C2C12 myocytes were grown in six-well plates and treated as above. Protein synthesis was measured on Day 3 in myoblasts following seeding or on day 7 following addition of DM in myotubes. For metabolic labeling 10 µCi of radiolabeled 35 Smethionine (MP Biologicals, PA) was added to each well of a 6 well plate and radiolabel incorporation into trichloroacetic acid (TCA) precepitable proteins were measured via liquid scintillation as previously described [22] .
Multiprobe template production for RNase protection assay. Primer selection for mouse genes of interest was determined using GeneFisher software [23] . The lengths of amplified regions were chosen to allow distinct resolution during electrophoretic separation. PCR was conducted with HotStarTaq DNA polymerase (Qiagen, Valencia, CA), and mouse total RNA was reverse transcribed with Superscript first-strand synthesis system for RT-PCR (Invitrogen). PCR products were phenol-chloroform extracted, ethanol precipitated, and sequentially digested with KpnI and EcoRI (Promega, Madison, WI). Digested products were gel purified, reextracted, and cloned into KpnI/EcoRI-digested pBluescript II SK+ (Stratagene, La Jolla, CA). Plasmid DNA was isolated with both QIAprep spin miniprep and plasmid maxi kits (Qiagen). Final constructs were linearized with EcoRI, gel purified, and quantitated spectrophotometrically. The template was prepared so that a 2 µl aliquot contained 10 ng each of PRAS40, S6K1, mTOR, 4E-BP1, and raptor, and 20 ng of L32.
RNA extraction and RNase protection assay. Total RNA was extracted from cells using Tri reagent (Molecular Research Center, Cincinnati, OH), exactly as previously described [24] . Concentration, purity, and integrity of the isolated RNA were assessed using a UV/VIS spectrophotometer (Beckman, Fullerton, CA). mRNA expression was determined by RNase protection assay. A 2 µl aliquot of template was prepared with T7 polymerase with buffer 
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sample preparation, and gel electrophoresis, was as published [24] . Gels were exposed to a PhosphorImager screen (Molecular Dynamics, Sunnyvale, CA), and data were visualized and analyzed by ImageQuant software (version 5.2; Molecular Dynamics). Signal densities within the linear range for mRNAs were normalized to densities for mouse ribosomal protein L32 mRNA.
Immunoblot analysis and immunoprecipitation. After treatment cells were rinsed 2x with cold DPBS and collected on ice in lysis buffer (20 mM HEPES [pH 7.4], 2 mM EGTA, 50 mM β-glycerophosphate, 0.3% CHAPS, 100 mM KCl, 2 mM EDTA, 50 mM NaF, 0.5 mM PMSF, 1 mM benzamidine, 1 mM sodium orthovanadate, and 2 µg/ml leupeptin). Lysates were sonicated for 10 min and then kept on a rocker for 30 min in the cold prior to being clarified (14000 x g for 10 min at 4°C). A portion of the resulting cell supernatant was used to determine protein concentration via a bicinchoninic acid assay (Pierce, Rockford, IL). Sample buffer (5x) was added and samples were loaded according to total protein content (20 µg) on polyacrylamide gels for separation by SDS-PAGE. Proteins were transferred to Polyvinylidene The PRAS40•raptor, PRAS40•eIF3f, and PRAS40•PRAS40 complexes were quantified as described [25] . Briefly, to maintain potential protein-protein interactions, cells were homogenized in CHAPS buffer as described above. The homogenate was mixed on a platform rocker and clarified by centrifugation. An aliquot (normalized to equal total protein) of the resulting supernatant was combined with anti-PRAS40 antibody and immune complexes isolated with a goat anti-rabbit BioMag IgG (PerSeptive Diagnostics, Boston, MA) beads. The beads were collected, washed with CHAPS buffer, precipitated by centrifugation, and subjected to SDS-PAGE as described above. Blots were then probed with appropriate antibodies to study protein-protein interaction and developed with ECL and analyzed as described above. MTT assay. C2C12 myoblasts (~10,000/well) were grown in a 96-well plate for 24 h and then rinsed with PBS to remove the interfering phenol red from the DMEM media. This was followed by the addition of methylthiazoletetrazolium (MTT; 50 µg/100 µl) to cells in each well for 4 h at 37°C [26] . MTT containing PBS was aspirated and 100 µl of DMSO was added to each well to dissolve the resulting formazan and absorbance at 570 nm was read in a plate reader Spectramax (Molecular Devices, Sunnyvale, CA).
DNA isolation and analysis.
To analyze nucleosomal DNA fragmentation, 2.5x10 6 C2C12 cells were processed as described by Zhivotovsky et al. [27] with minor modifications. 80% confluent cells were trypsinized and centrifuged for 5 min at 4000 rpm to removed media.
The cell pellet was resuspended in total DNA extraction buffer (400 mM NaCl; 10 mM Tris-HCl, pH 7.5; 10 mM EDTA with 50 µg/ml RNAse A and 0.2% SDS) and incubated at 37ºC overnight.
Proteinase K was added the following day to a final concentration of 50 µg/ml for 4 h at 37ºC. NaCl was then added to the DNA extraction mix to obtain a final concentration of 1.23 M and the extraction mix was left on ice overnight. The following day the mixture was centrifuged at 17,000 rpm for 1 h at 4ºC. The supernatant containing the low molecular weight DNA was removed and extracted 2x with phenol/chloroform followed by a final rinse in chloroform. shPRAS40 were seeded in 10 cm plates and photographed daily using a Nikon digital camera (Nikon Corp., Tokyo, Japan) mounted on a binocular microscope using 10x objective lens.
Images were composed and edited in Photoshop 7.0 (Adobe Systems Incorporated, San Jose, CA). Background was reduced using contrast and brightness adjustments to enhance reprint, and all modifications were applied to the whole image. Similarly treated plates were collected at days 3, 5, 7, and 9 for Western blotting to measure MHC expression as a functional end-point to measure differentiation biochemically as myoblasts were allowed to fuse and form differentiated post-mitotic myotubes. 
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Results
Effect of PRAS40 knockdown in C2C12 myotubes. C2C12 stable cell lines deficient in PRAS40 or scramble controls were created using short hairpin RNA (shRNA). shRNA were retrovirally delivered to myoblasts and some of these myoblasts were allowed to differentiate and form myotubes following puromycin selection. shRNA directed towards PRAS40 in myotubes reduced PRAS40 protein levels by greater than 80%, compared to scramble control values ( Fig. 1A and 1B) . As anticipated PRAS40 knockdown also reduced the PRAS40 mRNA content by ~65% in infected myotubes (Fig. 1C) . In contrast, PRAS40 knockdown did not alter the mRNA content for 4E-BP1, mTOR, S6K1 or raptor, proteins central to the functioning of the mTOR signaling pathway.
Knockdown of PRAS40 in differentiated myotubes did not alter global protein synthesis compared with scramble controls as measured by 35 S-methionine incorporation into protein ( Fig.   2A ). To determine whether the responsiveness of the PRAS40 knockdown cells to external stimuli was altered, cells were incubated with either an anabolic (IGF-I) or catabolic (AICAR) agent. Addition of IGF-I to the myotubes increased protein synthesis, whereas, AICAR inhibited protein synthesis ( Fig. 2A) . Contrary to expectations, the magnitude of the changes produced by these agents in myotubes was the same in both control and PRAS40 knockdown cells. To confirm protein synthesis data, we performed Western blotting for mTOR and its substrates and binding partners. PRAS40 knockdown cells remained responsive to both types of stimuli and their response was similar and comparable to the scramble controls (Fig. 2B) . For example, IGF-I increased phosphorylation of S6K1 (T389) and PRAS40 (T246), while AICAR increased raptor phosphorylation (S792).
PRAS40 knockdown decreases protein synthesis in C2C12 myoblasts. While the preceding data were obtained from post-mitotic differentiated myotubes (>95%), we also determined whether myoblasts would yield comparable results. In myoblasts, the knockdown of Molecular Medicine www.molmed.org
UNCORRECTED PROOF
PRAS40 decreased global protein synthesis by ~25% under basal conditions (Fig. 3A) . Despite the decrease in basal protein synthesis in the PRAS40 knockdown cells, the ability of these cells to respond positively or negatively to IGF-I or AICAR, respectively, was unaltered. Contrary to expectations, the decreased protein synthesis observed in PRAS40 knockdown cells under basal conditions was not associated with any difference in phosphorylation state of the mTOR substrates S6K1 and 4E-BP1, compared to the scramble control values (Fig. 3B) or changes in protein-protein interaction of PRAS40-raptor-eIF3 between the two groups (Fig. 3C) . In myoblasts, the ability of IGF-I to stimulate T389 phosphorylation of S6K1 and AICAR to increase S792 phosphorylation of raptor did not differ between scrambled and PRAS40 knockdown cells (Fig. 3D ).
PRAS40 knockdown alters myoblast cell size and proliferation. Vander Haar et al [21] reported that overexpression of wildtype PRAS40 decreased cell size in HEK 293 cells, whereas, knockdown of Lobe (a PRAS40 ortholog in Drosophila) increased cell size [15] .
Hence, we hypothesized that knocking down PRAS40 would also increase cell size in myocytes. PRAS40 knockdown increased the diameter (16.8 ± 0.1 µm) of low passage proliferating (~60% confluent) myoblasts compared to scramble control cells (14.0 ± 0.1 µm) as measured using either the Coulter counter particle size analyzer (Fig. 4A) or FACS flow cytometry analysis (data not shown). Mean cell volume was also increased in PRAS40 knockdown cells (Fig. 4B) . However, unexpectedly we found that PRAS40 knockdown cells grew slower compared to time-matched scramble controls (Fig. 5A ), although both cell types were seeded at the same initial density. To exclude anchorage-dependence and altered capacity to attach, cells were seeded and counted 4-8 h after seeding to allow for attachment.
An equal number of cells were harvested following trypsinization in both the control and PRAS40 knockdown cells, suggesting no significant difference in the ability of PRAS40 knockdown cells to attach to the culture plates (data not shown). To confirm that the proliferation rate of PRAS40 knockdown cells was slower, we used an independent colorimetric assay based Molecular Medicine www.molmed.org
on the conversion of the MTT tetrazolium salt to its formazan product. Consistent with the above presented data, the MTT assay revealed that PRAS40 knockdown cells had a 25% lower rate of proliferation (Fig. 5B ).
PRAS40 and apoptosis.
To determine whether increased apoptosis in PRAS40 knockdown cells was responsible for the slower proliferation rate, we isolated low molecular weight DNA and performed an apoptosis DNA laddering assay. Figure 6A illustrates there is no difference between the scramble control and the PRAS40 knockdown cells and that neither group of cells were undergoing active apoptosis within the detectable limits of the assay. These findings were confirmed by Western blotting for caspase-3/ PARP cleavage which failed to detect a significant difference between the groups. Myoblasts incubated with staurosporine were used as a positive control and demonstrated increased caspase-3 and PARP cleavage (Fig.   6B ). Collectively, these data suggest that the decreased protein synthesis and reduced proliferation in PRAS40 knockdown myoblasts cannot be attributed to increased apoptosis.
PRAS40 knockdown inhibits cell cycle progression.
To determine the mechanism for the lower proliferation rate in PRAS40 knockdown cells, we stained myoblasts with propidium iodide to study cell cycle events. PRAS40 knockdown myoblasts had a greater proportion of cells in G1/G0 of the cell cycle and fewer cells in active S -phase, compared to control values ( Fig. 7A and B, respectively; and Table 1 ).
Because PRAS40 knockdown cells were arrested in G1/G0 of the cell cycle we assessed whether proteins regulating cell cycle, especially the G1 -S transition, were concomitantly altered. Figure 7C illustrates there was a 25-30% reduction in S807/811 phosphorylation of Rb, consistent with reduced progression from G1 to S phase. In myoblasts with PRAS40 knockdown a 20-30% reduced expression of p21 was also detected in these cells.
There was no difference in the other proteins analyzed which regulate cell cycle -p53, cdk 4/6, p27 and cyclin D1 (Fig. 7D ). regulates autophagy which in turn plays an important role in cell differentiation [28, 29] , we determined the expression of proteins important in regulating autophagy. While there were no changes in the early markers for autophagy including, Atg 7 and Beclin 1 (Fig. 8A) , our data indicate that PRAS40KD decreased the ratio of LC3B-II/LC3B-I ( Fig. 8A and B) .
Next we determined whether such changes might be of physiological relevance to skeletal muscle development. In this regard, we seeded the same number of myoblasts and tracked their progression to form myotubes (Fig. 9) . We observed that control cells reached confluent status earlier than the PRAS40 knockdown and began fusion to form substantial number of myotubes by day 5, whereas PRAS40 knockdown cells only sparsely formed myotubes by day 5. These data suggest that myotube formation and myogenesis is delayed in PRAS40 knockdown cells.
To quantitate these findings, cell lysates were collected at various stages of development of myoblasts and myotubes to measure the expression of myosin heavy chain (MHC) -a protein expressed only in differentiated matured myotubes. While MHC expression was absent in myoblasts (day 3) and there was an initial delay in MHC expression in PRAS40 knockdown cells (days 5 and 7), by day 9 the expression of MHC in both scramble control and PRAS40 knockdown cells were comparable ( Fig. 10A and B) . The protein content of the muscle transcription factor MyoD did not differ between scramble control and PRAS40KD cells (Fig.   10A ).
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Discussion
In vitro studies performed in HEK293 and other rapidly dividing cell lines have identified PRAS40 as an mTORC1 binding protein and a regulator for mTOR activity [15, 16, 18, 21] . 
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cardiac hypertrophy) conditions. mTOR also plays an important role in regulating cell growth [8, [30] [31] [32] . In this regard, the over expression of PRAS40 decreases cell size in HEK293 cells.
Conversely, knockdown of PRAS40 in the same cells and of Lobe -an ortholog of PRAS40 in drosophila S2 cells -increased cell size [15, 21] . Consistent with these earlier observations, knockdown of PRAS40 in myoblasts also increased cell size. However, unexpectedly, PRAS40
knockdown cells were fewer in number, compared with the scramble controls. Furthermore, we observed that PRAS40 knockdown myoblasts had a slower rate of proliferation. This change could not be attributed to differential cell binding or attachment to the culture plates. Another potential explanation for the decreased cell number is increased apoptosis in myoblasts with PRAS40 knockdown. However, the role of PRAS40 in regulating apoptosis is controversial.
Whereas knockdown of PRAS40 inhibited tumor growth and proliferation via induction of apoptosis in melanoma cells [33] , PRAS40 knockdown reduced the ability of TNFα and cycloheximide to induce apoptosis in HeLa cells [34] . Using two different approaches -caspase 3 and PARP cleavage and DNA laddering -our data suggest that the lower proliferation rate in myoblasts could not be attributed to increased apoptosis. In general, it is believed that mTOR integrates signals to regulate cell size and cell cycle. However, increased cell size due to inhibition of myostatin was shown to be insensitive to rapamycin suggesting an mTORindependent regulation of muscle size. Also, maintenance of the hypertrophy during chronic myostatin deficiency does not require altered Akt/mTOR activity [35, 36] . Previously, Hentges et al implicated mTOR in regulating cell size and proliferation via different and independent mechanisms [37] . Therefore, although PRAS40 knockdown cells are larger than controls, cells deficient in PRAS40 have lower proliferation suggesting PRAS40 may potentially be an important modulatory binding partner of mTOR which uncouples cell size and cell cycle, thus, proliferation.
Molecular Medicine
www.molmed.org UNCORRECTED PROOF mTOR regulates cell cycle as evidenced by the ability of rapamycin to arrest cells in the G1 phase [4, 32, [37] [38] [39] [40] . Propidium iodide staining revealed that myoblasts with PRAS40 knockdown had a greater proportion of cells in the G1/G0 phase, compared to scramble controls, and fewer cells in the active S phase. Collectively, these data suggest PRAS40 is required for mTOR activity in regulating cell cycle and that knockdown of PRAS40 in myoblasts retarded cell cycle progression. Alternatively, we cannot exclude the possibility that the reduction in PRAS40 alters cell cycle kinetics by an undetermined mechanism which is mTORindependent. Since PRAS40 knockdown cells were arrested in G1/G0 of the cell cycle we focused on elucidating potential underlying mechanisms which might produce cell cycle arrest.
Regulation of cell cycle progression by the cyclin-dependent kinase (cdk) inhibitor p21 blocks cells from entering into the DNA synthesis (or S) phase in many cell types. The opposite role of p21 in skeletal muscle growth and differentiation, compared to its role in HEK293 cells, has received recent attention. In HEK293 cells, AICAR increased phosphorylation of p53 with an increased expression of p21 [41, 42] . While p21 null mice develop normally during embryogenesis [43] due to the presence and activation of another redundant cdk inhibitor -p57 [44] , myocytes from these mice have difficulty differentiating to myotubes [45] . C2C12 myoblasts treated with AICAR were arrested in G1 and H9c2 cardiomyocytes had reduced expression of p21 protein [42] . Since PRAS40 knockdown myoblasts were arrested in G1, we screened for proteins which regulate cell cycle especially in G1 -S transition. Retinoblastoma protein (pRb) regulates G1 exit in the cell cycle. Rb is phosphorylated upon mitogenic activation which disrupts Rb binding to E2F transcription factor thus allowing transcription of proteins which are essential for G1 -S transition. We found that after PRAS40 knockdown there was a reduction of pRb S807/811 phosphorylation consistent with reduced progression from G1 to S phase. In contrast, no change in the total amount of p53, cdk 4/6, cyclin D1 or p27 was detected. It has been reported that protein expression of p21 can be independent of these other regulatory proteins [46, 47] . However, we observed that similar to AICAR treatment, PRAS40 G1/G0 and reduced p21 expression in C2C12 myocytes produced by AICAR decreased cell cycling and delayed myotube formation [42] . To determine whether PRAS40 knockdown would delay myoblast fusion and thereby myotube formation, we monitored the progression and ability of these cells to form myotubes in culture. Time lapse imaging and Western blotting analysis for myosin heavy chain (a marker for matured myotubes) indicated that knockdown of PRAS40 in C2C12 myoblasts delayed myotube formation. Autophagy is another mTOR regulated cellular event that plays an important role in differentiation of myoblasts to mature myocytes [48] [49] [50] [51] .
Our results indicate that PRAS40KD decreases autophagy in myoblasts as inferred from the reduction in LC3BII/LC3B-I ratio. These changes suggest PRAS40 regulates muscle proliferation and differentiation via regulation of cell cycle and autophagy regulatory proteins.
In summary, PRAS40 knockdown in differentiated myotubes did not alter protein synthesis. In contrast, PRAS40 knockdown in C2C12 myoblasts decreased protein synthesis independent of a change in the phosphorylation of S6K1 and 4E-BP1, suggesting that PRAS40
is not a negative regulator of mTOR -mediated translation initiation in this cell type. Moreover, both myoblasts and myotubes remained responsive to anabolic and catabolic stimuli when PRAS40 was reduced. Knockdown of PRAS40 inhibited G1-S phase transition of cell cycle and lowered proliferation rate in myoblasts supporting the contention that PRAS40 is required for this aspect of mTOR signaling. Our data suggest that PRAS40 knockdown in C2C12 myoblasts impairs the ability of mTOR to regulate cell size and proliferation and that PRAS40 is required for these mTOR-associated functions. We confirm that PRAS40 plays an important role in regulation of cell size and show that it also affects cell proliferation and differentiation.
Understanding the role of PRAS40 in proliferation and differentiation of myocytes as outlined Myoblasts were seeded at the same density and counted using the Coulter counter as described in the Methods section. Time intervals are indicated in the figure; n = 5 for each treatment time point; experiments were repeated at least 3 times. Panel B: To measure proliferative rate acutely (24 h), an independent alternative approach using MTT was used.
Values are means ± SE for n = 32 for each condition; (*P <0.0001). and formation of myotubes. On Day 3 when the plates were fully confluent, the media was switched to 2% horse serum (DM = differentiation media) to induce myotube formation. 
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